2 months Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Cut to $1,050.00 by Analysts at Wells Fargo & Company MarketBeat
Wells Fargo & Company dropped their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday.
Nasdaq 100 · Pharmaceuticals · Regeneron Pharma (REGN) · Science · Wells Fargo&Co (WFC)
X